ARS Pharmaceuticals (SPRY) Capital Expenditures (2020 - 2025)
ARS Pharmaceuticals (SPRY) reported Capital Expenditures of -$5.5 million for Q3 2025, down 2215.33% on a YoY basis from $261000.0 in Q3 2024, and down 195.7% sequentially from $5.8 million in Q2 2025.
ARS Pharmaceuticals (SPRY) Capital Expenditures (2020 - 2025) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 6 years of Capital Expenditures data on file, last reported at -$5.5 million in Q3 2025.
- For the quarter ending Q3 2025, Capital Expenditures fell 2215.33% year-over-year to -$5.5 million; the trailing twelve-month figure through Mar 2026 stood at $248000.0 (down 56.57% YoY), and the FY2025 full-year result was $339000.0, down 39.79% from the prior year.
- Capital Expenditures eased to -$5.5 million in Q3 2025, from $5.8 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $5.8 million in Q2 2025 to a low of -$5.5 million in Q3 2025.
- A 5-year average of $70888.9 and a median of $83500.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures soared 13900.0% in 2021 and tumbled 2215.33% in 2025, its largest moves.
- Tracing SPRY's Capital Expenditures over 5 years: stood at -$822000.0 in 2021, then jumped by 115.33% to $126000.0 in 2022, then sank by 33.33% to $84000.0 in 2023, then soared by 259.52% to $302000.0 in 2024, then plunged by 1928.15% to -$5.5 million in 2025.
- Business Quant data shows SPRY's Capital Expenditures at -$5.5 million in Q3 2025, $5.8 million in Q2 2025, and $91000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 786,000.00 |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -5.52 Mn |
| Sep 30, 2025 | -5.52 Mn |
| Jun 30, 2025 | 5.77 Mn |
| Jun 30, 2025 | 5.77 Mn |
| Mar 31, 2025 | 91,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Sep 30, 2024 | 261,000.00 |
| Sep 30, 2024 | 261,000.00 |
| Jun 30, 2024 | -83,000.00 |
| Jun 30, 2024 | -83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Dec 31, 2023 | 84,000.00 |
| Dec 31, 2023 | 84,000.00 |
| Jun 30, 2023 | -102,000.00 |
| Jun 30, 2023 | -102,000.00 |
| Mar 31, 2023 | 193,000.00 |
| Mar 31, 2023 | 193,000.00 |